Performance and Safety of Exufiber Ag+ and Exufiber on Partial Thickness Burns
Public ClinicalTrials.gov record NCT04839523. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open, Non-comparative, Multi-center Investigation to Evaluate Performance and Safety of Exufiber Ag+ and Exufiber on Partial Thickness Burns
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This a multi-center, open label, non-comparative, study that will evaluate the clinical safety and performance of Exufiber Ag+ and Exufiber dressings, separately, when used as intended in moderate to high exuding partial thickness burns (PTBs) through assessment of wound progression from baseline to the Subject's last clinical follow-up visit. Sixty-eight (68) eligible subjects, with moderate to high exuding partial-thickness burns, will be selected for treatment with either Exufiber Ag+ silver-coated gelling dressing, or Exufiber gelling dressing. The study will last 5 weeks, with a requirement of 5 study visits in total, including dressing changes at each study visit.
Study identification
- NCT ID
- NCT04839523
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 44 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 4 Weeks and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 9, 2021
- Primary completion
- Dec 30, 2024
- Completion
- Dec 30, 2024
- Last update posted
- Nov 11, 2024
2021 – 2024
United States locations
- U.S. sites
- 6
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Burn Center, Valleywise Health | Phoenix | Arizona | 85008 | — |
| Keck Medical Center of USC | Los Angeles | California | 90033 | — |
| MedStar Health Research Institute | Washington D.C. | District of Columbia | 20010 | — |
| University of South Florida-Tampa General Hospital | Tampa | Florida | 33606 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Drexel Univerisity | Philadelphia | Pennsylvania | 19102 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Partial-thickness Burn trials
Other public records listing Partial-thickness Burn. Sorted by last update posted; newest first. Not a recommendation.
- NCT07453732: Banana Leaves as a Wound Dressing for Partial Thickness Second Degree Burns in Adult Patients. Not yet recruiting
- NCT06750809: Randomized Controlled Trial to Investigate Clinical Outcomes and Associated Costs When PermeaDerm is Used as Temporary Dressing for Surgical Wounds Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04839523, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 11, 2024 · Synced Jul 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04839523 live on ClinicalTrials.gov.